NCT05701215

Venetoclax After TKI to Target Persisting Stem Cells in CML

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Thomas Ernst, PD Dr. med. · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

There is currently no available treatment, capable to increase the rate of sustained deep molecular remissions after TKI discontinuation in CML. Venetoclax could be such a drug. The study will provide unprecedented biological insights on the effects of venetoclax in controlling minimal residual stem cell disease induced by long-term prior TKI therapy. If the study would be positive, the findings could become practice changing for patients in deep molecular remission under TKI and willing to tolerate a temporary additional treatment.

Conditions

• Chronic Myeloid Leukemia

Interventions

Type	Name	Description
DRUG	Venetoclax	Venetoclax will be taken orally once daily (400 mg) for 12 months

Timeline

• Start date: 2023-08-31
• Primary completion: 2026-01-31
• Completion: 2026-01-31
• First posted: 2023-01-27
• Last updated: 2025-03-10

Locations

2 sites across 1 country: Germany